Elan Prepares For A Buying Spree Now That Biogen Has Taken Over Tysabri
This article was originally published in The Pink Sheet Daily
Biogen Idec announced Feb.6 that it will pay $3.25 billion to its partner Elan for full rights to the multiple sclerosis drug Tysabri. The deal was not a surprise to Biogen investors, but it leaves Elan with a war chest of cash and virtually no commercial assets.
You may also be interested in...
The spec pharma’s latest MS offering surpasses $1 billion in sales as roll-out begins in Europe and focuses some of its resources toward its budding hemophilia franchise.
Paying cash up front to scientists, hospitals, biotechs and pharmas in exchange for their royalty stakes in successful drugs has proven profitable for Royalty Pharma. The firm has begun applying its long-term strategy to late-stage clinical candidates in addition to marketed products.
OTC private label leader Perrigo acquires Irish firm Elan for $8.6 billion in a deal that will bring tax savings from being incorporated in Ireland, provide a stage for European expansion and tap into Elan’s royalty rights. “Simply stated, we're going to be able to further our international platform,” CEO Joseph Papa says.